Nitinotes Begins EASE Clinical Trial Procedures in Italy
Caesarea, Israel, September 15, 2026 Nitinotes has announced the completion of the first EASE⢠clinical trial procedures at Fondazione...
AI drug discovery artificial intelligence Autoimmune Disease biologics Biomarkers biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cancer Treatment Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery FDA fda approval FDA clearance Gene Therapy healthcare technology Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology Oncology Ophthalmology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
Caesarea, Israel, September 15, 2026 Nitinotes has announced the completion of the first EASE⢠clinical trial procedures at Fondazione...
CAESAREA, Israel, July 28, 2026 Nitinotes Ltd. has completed the first study procedures at Orlando Health in its pivotal...
CAESAREA, Israel, Dec. 10, 2025 ā Nitinotes Ltd., an early commercial-stage medical technology company developing fully automated endoluminal suturing...
